These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 37270382)

  • 1. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
    Shirole NH; Kaelin WG
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):809-825. PubMed ID: 37270382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of
    Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
    Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
    Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
    Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
    Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
    Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
    Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
    Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
    Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
    Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
    Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
    Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
    Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
    Suárez C; Vieito M; Valdivia A; González M; Carles J
    Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer.
    Kaelin WG
    J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 36106637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
    Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
    Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
    Curry L; Soleimani M
    Future Oncol; 2024; 20(18):1251-1266. PubMed ID: 38639572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.
    Esteban MA; Tran MG; Harten SK; Hill P; Castellanos MC; Chandra A; Raval R; O'brien TS; Maxwell PH
    Cancer Res; 2006 Apr; 66(7):3567-75. PubMed ID: 16585181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.